Skip to main content
IMBdx, Inc. logo

IMBdx, Inc. — Investor Relations & Filings

Ticker · 461030 ISIN · KR7461030009 KO Human health and social work activities
Filings indexed 62 across all filing types
Latest filing 2023-08-18 Audit Report / Informat…
Country KR South Korea
Listing KO 461030

About IMBdx, Inc.

https://www.imbdx.com/eng/

IMBdx, Inc. is a precision oncology company specializing in liquid biopsy technology for cancer care. The company develops and provides diagnostic solutions that analyze genomic and epigenomic profiles of circulating tumor DNA (ctDNA) from a single blood draw. Its core technology, the AlphaLiquid platform, offers a suite of products for various clinical applications across the full continuum of cancer care. These applications include early-stage cancer screening (CancerFind), diagnosis, treatment selection through comprehensive genomic profiling (AlphaLiquid), and monitoring for recurrence (CancerDetect). The minimally-invasive tests are designed to provide safe, accurate, and personalized information to guide treatment decisions and improve patient outcomes.

Recent filings

Filing Released Lang Actions
[기재정정]감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'IMBDX' (주식회사 아이엠비디엑스). It contains an independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes to the financial statements. It specifically addresses a correction (정정) to previously filed financial statements due to valuation errors in equity-linked instruments. As it is a standalone audit report and not a full annual report (10-K), it falls under the Audit Report category. FY 2022
2023-08-18 Korean
감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'IMBDx' (주식회사 아이엠비디엑스) for the fiscal year ending December 31, 2022. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial report prepared by an external auditor, which fits the definition of an Audit Report (AR). FY 2022
2023-04-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.